The street leaned constructive this week. Upgrades outnumbered downgrades across the 22 analyst actions logged in the period of August 17–21. Financials, REITs, and semiconductors drew the most attention. Keefe, Bruyette & Woods and Barclays were among the most active firms, moving in opposite directions on insurance and infrastructure names.
Barclays upgraded AMT to Overweight, lifting the price target to $198 from $195. Short interest on the tower REIT has fallen 2.4% over the past month to 1.6% of free float.
Barclays also upgraded CCI to Overweight from Equal-Weight. Analyst Brendan Lynch cut the price target to $84 from $92, still implying 11% downside from the $75.39 close. The rating lift came despite the target reduction.
KeyBanc upgraded EPR to Overweight from Sector Weight, setting a $70 price target. That implies 14% upside from the $61.22 close. The experiential REIT carries 9.2% short interest as a share of free float, though that figure has declined 6.7% over the past month.
Keefe, Bruyette & Woods upgraded PGR to Outperform, raising the price target 10.6% to $250. The firm cited conviction despite recent price weakness and mixed street sentiment.
Rothschild & Co upgraded EFX to Buy with a $235 price target. The stock closed at $192.41, placing consensus-implied upside at roughly 22%.
Bernstein upgraded ADI to Outperform, lifting the target to $465 from $430. The stock traded at $370.24 at the time — 25.6% below the new target.
William Blair upgraded MRNA to Outperform from Market Perform. The call landed on a difficult session: the stock fell 23.5% on the day. Short interest remains elevated at 12.6% of free float.
Morgan Stanley upgraded TX to Overweight, raising the target 18% to $65.
KeyBanc upgraded INNV to Overweight with a $13 price target, implying 21% upside from $10.72. Short interest has dropped 29% over the past month.
JP Morgan upgraded TIC to Neutral from Underweight, raising the target 22% to $11. The stock traded at $9.02, with short interest declining.
Wells Fargo upgraded POR to Overweight, lifting the target 14% to $58 versus a $50.17 close.
Citigroup upgraded OI to Buy from Neutral, raising the price target 12.5% to $9. O-I Glass has fallen 28% this month on weak beverage demand.
Baird upgraded PSN to Outperform with a $57 target — 18.75% above the prior $48 estimate. Short interest sits at 5.88% of free float, down 1.86% over the past week.
RBC Capital downgraded MRK to Sector Perform, though the firm raised the price target to $150. The stock closed at $148.99, up 19.8% year-to-date. RBC flagged post-Q2 headwinds and a broader analyst re-rating cycle.
Keefe, Bruyette & Woods downgraded ALL to Underperform, cutting the target to $250 from $255. Short interest in Allstate collapsed 24.5% in a single week to just 2.3% of free float ahead of the call.
Citigroup downgraded TJX to Neutral, cutting the target 15% to $154. That implies 9% downside from the $140.69 close.
Baird downgraded TER to Neutral. The target was held at $420, leaving a constructive street consensus intact.
JP Morgan downgraded LMB to Underweight, cutting the price target 17% to $50 from $60.
Citigroup downgraded WHD. The action came despite a price target increase — an unusual split signal. The stock fell 6.6% on the day, closing at $68.85.
Morgan Stanley downgraded LILA to Underweight. Short interest climbed 21% in a single week to 2.7% of free float around the time of the action.
JP Morgan downgraded DV to Neutral. The move follows the announced Nielsen deal, with the stock now trading as a merger arbitrage play.
Citigroup downgraded WB to Neutral, cutting the price target 16% to $7.80.
Tower and specialty REITs drew concentrated analyst attention. Barclays upgraded both AMT and CCI to Overweight. The CCI target cut alongside the upgrade reflects ongoing caution on tower fundamentals despite the positive rating shift. KeyBanc added EPR with a bullish call on experiential real estate recovery.
KBW was the dominant firm in financials. It upgraded PGR to Outperform while simultaneously downgrading ALL to Underperform. The divergence suggests the firm sees meaningful valuation dispersion within the insurance sector. The sharp collapse in Allstate short interest ahead of the downgrade is notable.
ADI and TER both received attention, but with opposite conclusions. Bernstein pushed ADI to Outperform with a high-conviction $465 target. Baird moved the other way on Teradyne, cutting to Neutral while holding the target. The split reflects differing views on the analog and test equipment segments of the chip supply chain.
William Blair's upgrade of MRNA stands out as the week's most contrarian action. The Outperform call arrived on a session where the stock dropped 23.5%. Short interest remains high at 12.6% of free float. The divergence between analyst optimism and market reaction — and elevated short positioning — makes this one to watch.
ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
